Logo image of AXLA

AXCELLA HEALTH INC (AXLA) Stock Fundamental Analysis

NASDAQ:AXLA - US05454B2043 - Common Stock

4.58 USD
-0.9 (-16.42%)
Last: 11/22/2023, 8:00:01 PM
3.42 USD
-1.16 (-25.33%)
After Hours: 11/22/2023, 8:00:01 PM
Fundamental Rating

0

Overall AXLA gets a fundamental rating of 0 out of 10. We evaluated AXLA against 545 industry peers in the Biotechnology industry. Both the profitability and financial health of AXLA have multiple concerns. AXLA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AXLA has reported negative net income.
In the past year AXLA has reported a negative cash flow from operations.
AXLA had negative earnings in each of the past 5 years.
AXLA had a negative operating cash flow in each of the past 5 years.
AXLA Yearly Net Income VS EBIT VS OCF VS FCFAXLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

AXLA's Return On Assets of -518.60% is on the low side compared to the rest of the industry. AXLA is outperformed by 98.67% of its industry peers.
Industry RankSector Rank
ROA -518.6%
ROE N/A
ROIC N/A
ROA(3y)-197.72%
ROA(5y)-140.01%
ROE(3y)-767.28%
ROE(5y)-495.06%
ROIC(3y)N/A
ROIC(5y)N/A
AXLA Yearly ROA, ROE, ROICAXLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AXLA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AXLA Yearly Profit, Operating, Gross MarginsAXLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for AXLA has been increased compared to 1 year ago.
There is no outstanding debt for AXLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AXLA Yearly Shares OutstandingAXLA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M 2.5M
AXLA Yearly Total Debt VS Total AssetsAXLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

AXLA has an Altman-Z score of -78.43. This is a bad value and indicates that AXLA is not financially healthy and even has some risk of bankruptcy.
AXLA's Altman-Z score of -78.43 is on the low side compared to the rest of the industry. AXLA is outperformed by 98.84% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -78.43
ROIC/WACCN/A
WACCN/A
AXLA Yearly LT Debt VS Equity VS FCFAXLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 0 50M -50M

2.3 Liquidity

A Current Ratio of 0.81 indicates that AXLA may have some problems paying its short term obligations.
With a Current ratio value of 0.81, AXLA is not doing good in the industry: 92.37% of the companies in the same industry are doing better.
AXLA has a Quick Ratio of 0.81. This is a bad value and indicates that AXLA is not financially healthy enough and could expect problems in meeting its short term obligations.
AXLA's Quick ratio of 0.81 is on the low side compared to the rest of the industry. AXLA is outperformed by 91.71% of its industry peers.
Industry RankSector Rank
Current Ratio 0.81
Quick Ratio 0.81
AXLA Yearly Current Assets VS Current LiabilitesAXLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.38% over the past year.
EPS 1Y (TTM)42.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AXLA will show a small growth in Earnings Per Share. The EPS will grow by 3.37% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y86.67%
EPS Next 2Y36.63%
EPS Next 3Y22.98%
EPS Next 5Y3.37%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AXLA Yearly Revenue VS EstimatesAXLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 5M 10M 15M 20M
AXLA Yearly EPS VS EstimatesAXLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -20 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AXLA. In the last year negative earnings were reported.
Also next year AXLA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AXLA Price Earnings VS Forward Price EarningsAXLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AXLA Per share dataAXLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as AXLA's earnings are expected to grow with 22.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.63%
EPS Next 3Y22.98%

More info and screens

0

5. Dividend

5.1 Amount

AXLA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AXCELLA HEALTH INC

NASDAQ:AXLA (11/22/2023, 8:00:01 PM)

After market: 3.42 -1.16 (-25.33%)

4.58

-0.9 (-16.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2023-11-14/bmo
Earnings (Next)03-28 2024-03-28/amc
Inst Owners0%
Inst Owner Change-42.86%
Ins Owners190.4%
Ins Owner Change0%
Market Cap13.51M
Analysts82.5
Price Target15870.1 (346408.73%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)43.83%
Min EPS beat(2)18.3%
Max EPS beat(2)69.36%
EPS beat(4)3
Avg EPS beat(4)23.12%
Min EPS beat(4)-7.84%
Max EPS beat(4)69.36%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)275733%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2400%
EPS NY rev (1m)0%
EPS NY rev (3m)-2172.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-19.25
EYN/A
EPS(NY)-5.1
Fwd EYN/A
FCF(TTM)-14.59
FCFYN/A
OCF(TTM)-14.52
OCFYN/A
SpS0
BVpS-0.75
TBVpS-0.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -518.6%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-197.72%
ROA(5y)-140.01%
ROE(3y)-767.28%
ROE(5y)-495.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 85.19%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.81
Quick Ratio 0.81
Altman-Z -78.43
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)86.19%
Cap/Depr(5y)68.29%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.5%
EPS Next Y86.67%
EPS Next 2Y36.63%
EPS Next 3Y22.98%
EPS Next 5Y3.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y41.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.77%
OCF growth 3YN/A
OCF growth 5YN/A